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MedicareAims: Type 2 diabetes (T2D) accelerates progression of chronic liver disease to cirrhosis, yet the effects of most
glucose-lowering drugs (GLDs) on cirrhosis risk in T2D are unknown. To address this gap, we compared cirrhosis
risk following initiation of newer second-line GLDs vs. thiazolidinediones (TZDs), which improve histology in
non-alcoholic fatty liver disease.
Materials and methods: Using the US Medicare Fee-for-Service database (2007–2015) and an active comparator,
new-user design,we estimated crude incidence rates (IRs) and propensity-score adjustedhazard ratios (aHR) for
incident cirrhosis, comparing newer GLDs (dipeptidyl peptidase-4 inhibitors (DPP4i), glucagon-like peptide-1
receptor agonists (GLP1RA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i)) vs. TZDs.
Results: Among 239,549 total initiators, we observed 318, 151, and < 30 cirrhosis events when comparing DPP4i
vs. TZD, GLP1RA vs. TZD, and SGLT2i vs. TZD, respectively. IRs ranged from 1.7 [95% CI, 0.8–3.6] to 3.6 [2.5–5.2]
events per 1000 person-years. Point aHR estimates for cirrhosis were elevated among newer GLD initiators vs.
TZD (DPP4i: 1.15 [0.89–1.50]; GLP1RA: 1.34 [0.82–2.20]; SGLT2i: 1.16, [0.44–3.08]), although estimateswere im-
precise due to short durations of drug exposure.
Conclusions:We observed mildly elevated cirrhosis risk with newer GLDs vs. TZD; however, uncertainty remains
due to imprecise and statistically non-significant effect estimates.1. Introduction
Cirrhosis signifies late-stage chronic liver disease (CLD) resulting
from many causes, including hepatitis B/C infection, alcohol-related
liver disease and non-alcoholic fatty liver disease (NAFLD). Mortality
due to cirrhosis has been rising,1 increasing by 72% between 1999 and
2017.2 Type 2 diabetes (T2D) is a potent risk factor for progression of
hepatic steatosis to advanced fibrosis in NAFLD,3 and the presence of
T2D also heightens risk of cirrhosis from other etiologies,4 including
hepatitis B,5 hepatitis C,6 and alcoholic liver disease.7 Despite T2D
being a recognized risk factor for progressive liver disease, little is
known about how glucose-lowering drugs (GLDs) influence risk of all-
cause cirrhosis.Hall, Campus Box#7435, ChapelThiazolidinediones (TZD) are insulin sensitizers with favorable lipid
effects, and are known to improve steatosis andfibrosis in non-alcoholic
steatohepatitis.8,9 Notably, reduction of hepatic fat by TZDs may also be
beneficial in other forms of liver disease, such as with viral hepatitis.10
Newer GLDs, including dipeptidyl peptidase-4 inhibitors (DPP4i),
glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-
glucose cotransporter-2 inhibitors (SGLT2i), have only been explored
for their benefits in NAFLD.11,12 Both GLP1RA and SGLT2i improve
NAFLD by promoting weight loss; weight-independent effects may
also exist.12,13 DPP4i do not appear to have a substantial impact on
NAFLD, though data are mixed.12–16
Since T2D likely mediates progression of all-cause liver disease by
promoting steatohepatitis, and since GLDs have varying liver effects, it
is plausible that GLDs differentially modify cirrhosis risk in patients
with T2D and CLD, regardless of etiology. Currently, there is insufficient
evidence to recommendoneGLDover another to reduce risk of cirrhosis
in T2D.We aimed to address this gap by estimating the comparative ef-
fect of multiple newer second-line GLDs (DPP4i, GLP1RA, SGLT2i) vs.
TZD on risk of incident cirrhosis of any etiology in older adult patients
with T2D.
2. Materials and methods
2.1. Data source
We conducted an active comparator, new-user (ACNU) retrospec-
tive cohort study,17 using a nationwide 20% random sample of the US
Medicare Fee-for-Service (FFS) database. The Medicare FFS database is
representative of the US population aged ≥65, with information on
Part A (inpatient services), Part B (outpatient services), and Part D (pre-
scription drug) coverage, as well as enrollment and demographic
information.
2.2. Study population
The base population consisted of all patients with ≥1 prescription
dispensing claim for a SGLT2i, DPP4i, GLP1RA, or TZD between January
1, 2007 and September 30, 2015, identified using National Drug Codes
(NDCs).We conducted three pairwise comparisons (Appendix Tables 1,
2) to estimate the comparative risk of cirrhosiswith newer GLDs vs. TZD
(DPP4i vs. TZD, GLP1RA vs. TZD, and SGLT2i vs. TZD). Pairwise compar-
isons involving SGLT2i were only conducted using data from 2013 to
2015, since SGLT2i were not in routine use in the US before 2013. We
additionally compared the three newer GLDs (SGLT2i vs. GLP1RA,
SGLT2i vs. DPP4i, and DPP4i vs. GLP1RA); however, we observed gener-
ally unstable estimates due to limited drug use data in these compari-
sons, and report these analyses in the Appendix.
Eligible patientswere adults aged ≥65 yearswith ≥12months of con-
tinuous enrollment in Parts A, B, and D prior to first eligible prescription
dispensing claim. To ensure new use of the study drugs, we excluded
patients who received a prescription for either drug in each pairwise
comparison during the12-month baselineperiod leadingup to drug ini-
tiation (washout period). To remove patients with prevalent cirrhosis,
we excluded individuals with the following conditions in the 12-
month baseline period: 1) previous diagnosis of cirrhosis in either clinic
or hospital setting (ICD-9-CM diagnoses 456.0; 456.1; 456.2; 456.21;
567.23; 571.2; 571.5; 572.2; 572.3; 572.4; 789.59, which achieves a sen-
sitivity of 98–99% for exclusion)18; 2) previous diagnosis of hepatocellu-
lar carcinoma or cholangiocarcinoma; or 3) prior hepatectomy or liver
transplantation (Appendix Figs. 1, 2).
The studywas exempted from full Institutional ReviewBoard review
by the University of North Carolina at Chapel Hill. The study protocol
was registered with the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance, prior to estimating
treatment effects on cirrhosis (EU PAS Register Number 31539).
2.3. Exposure
Exposure was defined as ≥2 same-drug class prescription dispensing
claims of the study drugs in each pairwise comparison. To simulate on-
going use of the initial treatment, we permitted the second prescription
to occur within 30 days (grace period) following the first prescription's
days' supply, to allow for leeway between prescription fills. The second
prescription served as the index date for the analysis. We excluded pa-
tients who received a prescription for the comparator drug between the
first and second prescriptions of the index drug, and vice versa.
2.4. Outcome
The primary outcome of interest (Appendix Table 3) was the first
diagnosis of cirrhosis, defined by any of the following ICD-9-CM di-
agnosis codes in the hospital setting: 456.1, 571.2, or 571.5 (cirrhosis
definition 1).18 Due to the lack of a standard, validated claims-based
definition for cirrhosis, we also assessed the impact of alternativedefinitions of cirrhosis (Appendix Table 3), including a more sensi-
tive definition that uses the same codes as our primary definition,
but in either outpatient or hospital settings (cirrhosis definition 2).18
2.5. Follow-up
We conducted the primary analysis using an “as-treated” approach,
where follow-up started at the index date (date of the 2nd prescription)
and ended at the time an individual experienced either an outcome of
interest or censoring event (Appendix Fig. 3). Patients were censored
for treatment discontinuation, switch or augmentation; disenrollment
fromMedicare Parts A, B, or D; or at the administrative study end (Sep-
tember 30, 2015), whichever came first.
Patients were considered to have discontinued treatment if they re-
ceived no new prescription of the cohort drug class within a (prescrip-
tion days' supply + pre-defined 30-day grace period) time window
after the last prescription of the cohort drug class; censoring occurred
at the end of this window. Similarly, patients were considered to have
switched or augmented treatment if they filled a prescription for a com-
parator drug within the same timewindow after the last prescription of
the cohort drug class; censoring occurred at the fill date of the compar-
ator drug class. Patients who switched between, or augmented with,
drugs within the same class were not censored.
2.6. Confounding control
We controlled for measured confounding using propensity score
weighting, with the following baseline covariates, measured in the 12
months prior to index date, included in the propensity score model:
1) patient demographics (age, sex, race, low income subsidy);
2) diabetes-related comorbidities (retinopathy, nephropathy, neuropa-
thy); 3) liver-related diseases (viral hepatitis B and C, alcoholic liver dis-
ease, non-alcoholic fatty liver disease, drug-induced liver injury);
4) cardiovascular comorbidities (hypertension, dyslipidemia, coronary
artery disease, cerebrovascular disease, peripheral vascular disease,
congestive heart failure); 5) general health comorbidities (chronic kid-
ney disease, chronic obstructive pulmonary disease, depression, alco-
holism, obesity, smoking status; 6) diabetic medication use
(metformin, sulfonylurea, long-acting insulin, and any TZD, DPP4i,
GLP-1RA, SGLT2i not used to define cohorts); 7) other medication use
(angiotensin-converting enzyme inhibitor, angiotensin receptor
blockers, beta-blockers, calcium channel blockers, statins, aspirin, pre-
scription omega-3 fatty acids, and various diuretics [loop, thiazide, aldo-
sterone antagonists, and other]); and 8) measures of healthcare
utilization (number of hemoglobin A1c tests, number of low-density li-
poprotein (LDL) tests, hospitalizations, emergency department visits,
physician encounters, gastroenterologist encounters, endocrinologist
encounters).
2.7. Statistical analysis
We estimated propensity scores using multivariable logistic regres-
sion and applied them via standardized mortality ratio (SMR)
weighting to estimate the average treatment effect in the treated, by
reweighting the comparator drug initiators by the propensity score
odds (PS/(1-PS))19 within each pairwise comparison. This approach
seeks to address the question: “what would the observed cirrhosis
risk have been if all patients who initiated a newer GLD instead initiated
a TZD?” Covariate balance before and after SMR weighting was evalu-
ated using the standardized mean difference (SMD). Asymmetric 1%
propensity score trimming was used to remove some patients treated
contrary to prediction to reduce the potential for unmeasured
confounding.20
To compare incidence of cirrhosis, we estimated crude incidence
rates (IR) and 95% confidence intervals (CIs) using Poisson regression,
as well as crude and adjusted hazard ratios (aHRs) using SMR-
weighted Cox proportional hazards models. Finally, we generated cu-
mulative incidence curves for cirrhosis using weighted Kaplan-Meier
methods.
2.8. Sensitivity and subgroup analysis
We conducted a number of sensitivity and subgroup analyses to as-
sess the impact of various study specifications and definitions. First, we
used an initial treatment (IT) approach, ignoring censoring for treat-
ment changes during follow-up (similar to intention-to-treat analyses
in randomized clinical trials). Second, we applied 30-, 60-, 90-, 180-,
and 270-day induction and latency periods to account for possible diag-
nostic delay of cirrhosis, where follow-up started e.g., 90 days after
index date, and continued for outcomes 90 days after censoring for
treatment discontinuation, switch, or augmentation. Third, we re-
estimated HRsmodeling death as a competing event in the Cox propor-
tional hazards model, using the Aalen-Johansen estimator. To assess the
robustness of the SMR weighting approach, we repeated the analysis
using a multivariable Cox proportional hazard model. Finally, to assess
whether the estimated HRs varied over calendar time, we restricted
all analyses to the same 2013–2015 calendar period.
We also repeated the primary analysiswithin pre-defined, clinically-
relevant patient subgroups: 1) patients with/without metformin use
during the baseline period; 2) patients with/without baseline liver dis-
ease; 3) patients aged 66–75, >75; and 4) men vs. women. In post-
hoc analyses, we additionally assessed effect measure modification
among 1) patients with/without baseline insulin use; 2) patients with




We identified 239,549 patients with initiation of any of the study
drugs during the study window. Of those, 103,491 patients were in-
cluded in the DPP4i (n = 69,027) vs. TZD (n = 34,464) comparison,
52,473 in the GLP1RA (n = 10,728) vs. TZD (n = 41,745) comparison,
and 18,829 in the SGLT2i (n= 7849) vs. TZD (n= 10,980) comparison
(Appendix Fig. 1, Table 1).
Initiators of TZDs exhibited higher proportions of male and non-
white patients compared to initiators of the three newer second-line
GLDs. Comorbidities were generally more prevalent among initiators
of newer GLDs; we observed the largest crude differences between
baseline covariate distributions in the SGLT2i vs. TZD comparison (Ap-
pendix Figs. 4, 5), relative to other comparisons. Prevalence of codes
for baseline obesity, as well as the proportion of patients with DPP4i
and insulin use during the baseline period, were notably elevated in
GLP1RA and SGLT2i users. TZD initiators, on the other hand, had higher
prevalence of renal disease compared to SGLT2i initiators, and generally
more prior sulfonylurea and ACEI use. Covariate balance was improved
by SMR weighting (Appendix Fig. 5).
3.2. Incidence of cirrhosis
In primary as-treated analysis, we observed 318, 151, and <30 cir-
rhosis events when comparing DPP4i vs. TZD, GLP1RA vs. TZD, and
SGLT2i vs. TZD, respectively. Crude incidence rates of cirrhosis ranged
from 1.7 [95% CI, 0.8–3.6] events per 1000 person-years in the SGLT2i
cohort, to 3.6 [2.5–5.2] events per 1000 person-years in the GLP1RA co-
hort, and were generally higher among patients treatedwith DPP4i and
GLP1RA, vs. TZD (Table 2). After weighting, we observed elevated aHR
point estimates for all three newer second-line GLDs (Table 2). Com-
pared to TZD initiators, the estimated hazard for cirrhosis was most el-
evated for GLP1RA initiators (aHR 1.34, 95% CI 0.82–2.20), followed by
SGLT2i initiators (aHR 1.16, 95% CI 0.44–3.08) and DPP4i initiators(aHR 1.15, 95% CI 0.89–1.50). The elevated aHR estimates in the
GLP1RA comparisonwere supported by separation of the cumulative in-
cidence curves (Fig. 1), although curves crossed after 420 days of follow-
up, likely due to low numbers of patients at-risk in the GLP1RA group.
Alternative cirrhosis definitions yielded further-increased aHR esti-
mates among newer GLD users for all TZD comparisons (Table 3, Fig. 1).
3.3. Subgroup and sensitivity analyses
Results remained generally consistent across a number of sensitivity
analyses (Fig. 2). In all TZD comparisons, aHR estimates were elevated
among patients who were younger (age ≤75), female, and who had a
history of liver disease. Hazards also appeared to be increased among
patients who self-identified as non-white in the GLP1RA and SGLT2i
comparisons, while the reverse was observed in the DPP4i comparison.
Subgroup aHR estimates were generally imprecise in all comparisons
involving SGLT2i due to few observed events.
4. Discussion
This is the first study examining the comparative effect of second-
line glucose-lowering drugs (GLDs) on risk of incident cirrhosis in pa-
tients with T2D. In general, point estimates suggested a possible trend
towards lowest cirrhosis risk with TZD compared to newer second-
line GLDs, which was largely consistent across a number of sensitivity
analyses. However, short exposure durations to the study drugs yielded
wide 95% CIs and limited our ability to draw strong conclusions from
these data.
We chose to compare newer GLDs to TZD since less is known about
the liver effects of these newer agents, whereas TZD have well-
established benefits in NAFLD; including resolution of non-alcoholic
steatohepatitis and improvement in fibrosis.8,21,22 GLP1RA and SGLT2i
are associated with weight loss and preliminary evidence also suggests
benefit in NAFLD,23–26 so we included these agents as comparisons. Ad-
ditionally, we examined DPP4i since they are the most commonly pre-
scribed branded second-line GLD,27 and there is conflicting evidence
regarding their impact on NAFLD.13–16 Despite sulfonylureas being the
most commonly prescribed second-line agent in T2D,27 they are sub-
stantially cheaper than newer agents, so were excluded given potential
for socioeconomic confounding.
4.1. Impact of glucose-lowering drugs on cirrhosis appears to mirror NAFLD
literature
Our findings on the impact of GLDs and cirrhosis risk follow similar
patterns to those seen in NAFLD. For instance, TZD have the strongest
evidence for benefit in NAFLD, and we likewise observed HR estimates
consistently above 1 for newer GLD vs. TZD comparisons in as-treated,
propensity score-weighted analyses. Both GLP1RA and SGLT2i have
been shown to improve liver enzymes and reduce hepatic steatosis in
patients with T2D and NAFLD.23,25,26,28 Few randomized controlled tri-
als (RCTs) have compared these agents to TZD, and they position
GLP1RA and SGLT2i as either similar or better than TZD at improving
liver enzymes and histology.29–32 In our study, we observed slightly
higher estimated hazards of incident cirrhosis among both GLP1RA
and SGLT2i initiators compared to TZD initiators, although aHR esti-
mates were reduced in the GLP1RA analysis when including outpatient
and expanded cirrhosis diagnosis codes. Precision was also limited for
our SGLT2i comparisons, with fewer years of SGLT2i data (2013–
2015) likely contributing to this uncertainty.
DPP4i use was associated with higher estimated hazard of incident
cirrhosis compared to TZD, particularly when using cirrhosis definitions
with greater sensitivity (i.e., definitions 2 and 4). This trendmay reflect
DPP4i's more neutral effect observed in NAFLD.12 Interestingly, serum
dipeptidyl peptidase 4 (DPP4) levels are elevated in NASH, and are pos-
itively associatedwith histopathological grade and fibrosis.33,34 A recent
Table 1
Baseline characteristics of eligible initiators of DPP4i vs. TZD, GLP1RA vs. TZD, and SGLT2i vs. TZD, before and after implementation of standardizedmortality ratio (SMR)Weightinga (365-
day washout period, 1% asymmetric propensity score trimming).


























Age, mean (std. dev.) 74.1 (7.1) 72.9 (6.9) 74.0 (7.1) 70.7 (5.3) 73.1 (6.9) 70.6 (5.3) 71.6 (5.6) 73.0 (6.8) 71.6 (5.6)
Male 28,015 (40.6) 15,281 (44.3) 27,907 (40.5) 4349 (40.5) 18,512 (44.3) 4263 (39.9) 3840 (48.9) 5371 (48.9) 3887 (48.7)
Race
White 52,040 (75.4) 25,123 (72.9) 52,178 (75.6) 9074 (84.6) 30,056 (72.0) 9059 (84.7) 6446 (82.1) 8263 (75.3) 6622 (82.9)
Black 7499 (10.9) 4035 (11.7) 7315 (10.6) 873 (8.1) 4765 (11.4) 883 (8.3) 565 (7.2) 1056 (9.6) 553 (6.9)
Other 9488 (13.7) 5306 (15.4) 9486 (13.8) 781 (7.3) 6924 (16.6) 748 (7.0) 838 (10.7) 1661 (15.1) 809 (10.1)
Diabetes comorbiditiesb
Nephropathy 5769 (8.4) 2353 (6.8) 5791 (8.4) 1182 (11.0) 3115 (7.5) 1176 (11.0) 634 (8.1) 1178 (10.7) 661 (8.3)
Neuropathy 13,480 (19.5) 5465 (15.9) 13,640 (19.8) 2666 (24.9) 7096 (17.0) 2685 (25.1) 1959 (25.0) 2169 (19.8) 2043 (25.6)
Retinopathy 10,414 (15.1) 4893 (14.2) 10,392 (15.1) 1925 (17.9) 6248 (15.0) 1913 (17.9) 1438 (18.3) 1609 (14.7) 1430 (17.9)
Peripheral vascular disease 9521 (13.8) 3977 (11.5) 9508 (13.8) 1208 (11.3) 5000 (12.0) 1231 (11.5) 920 (11.7) 1213 (11.0) 964 (12.1)
General health comorbiditiesb
Alcoholic liver disease 31 (0.0) 16 (0.0) 30 (0.0) NTSRc 17 (0.0) NTSR NTSR NTSR NTSR
Alcohol abuse 320 (0.5) 179 (0.5) 314 (0.5) 29 (0.3) 212 (0.5) 27 (0.3) 19 (0.2) 20 (0.2) 23 (0.3)
AMI 3283 (4.8) 1176 (3.4) 3247 (4.7) 465 (4.3) 1446 (3.5) 457 (4.3) 320 (4.1) 389 (3.5) 290 (3.6)
Cerebrovascular disease 13,204 (19.1) 5518 (16.0) 13,124 (19.0) 1564 (14.6) 6842 (16.4) 1596 (14.9) 1233 (15.7) 1563 (14.2) 1287 (16.1)
CHF (exclusion) – – – – – – – – –
CKD 12,073 (17.5) 4743 (13.8) 12,080 (17.5) 1888 (17.6) 6173 (14.8) 1894 (17.7) 939 (12.0) 2208 (20.1) 975 (12.2)
Coagulopathy 2377 (3.4) 935 (2.7) 2417 (3.5) 287 (2.7) 1167 (2.8) 287 (2.7) 213 (2.7) 278 (2.5) 204 (2.6)
COPD 15,371 (22.3) 6704 (19.5) 15,265 (22.1) 2431 (22.7) 8182 (19.6) 2387 (22.3) 1585 (20.2) 2064 (18.8) 1678 (21.0)
Decompensation 3532 (5.1) 1182 (3.4) 3525 (5.1) 391 (3.6) 1505 (3.6) 378 (3.5) 195 (2.5) 446 (4.1) 199 (2.5)
Depression 10,174 (14.7) 4163 (12.1) 10,116 (14.7) 1717 (16.0) 5087 (12.2) 1685 (15.8) 1088 (13.9) 1388 (12.6) 1132 (14.2)
Diabetes 66,541 (96.4) 31,795 (92.3) 66,456 (96.3) 10,289 (95.9) 38,887 (93.2) 10,252 (95.9) 7750 (98.7) 10,290 (93.7) 7885 (98.8)
Drug induced liver 513 (0.7) 281 (0.8) 537 (0.8) 66 (0.6) 371 (0.9) 67 (0.6) 44 (0.6) 53 (0.5) 50 (0.6)
Dyslipidemia 57,787 (83.7) 26,207 (76.0) 57,698 (83.6) 9130 (85.1) 32,418 (77.7) 9069 (84.8) 7053 (89.9) 8936 (81.4) 7186 (90.0)
HIV 125 (0.2) 72 (0.2) 133 (0.2) 13 (0.1) 93 (0.2) 15 (0.1) NTSR 19 (0.2) NTSR
Ischemic heart disease 22,087 (32.0) 9052 (26.3) 21,991 (31.9) 3295 (30.7) 11,359 (27.2) 3324 (31.1) 2409 (30.7) 2827 (25.7) 2451 (30.7)
Liver disease 155 (0.2) 65 (0.2) 153 (0.2) 13 (0.1) 90 (0.2) 13 (0.1) 23 (0.3) 19 (0.2) 17 (0.2)
Non-alcoholic liver disease 1840 (2.7) 680 (2.0) 1874 (2.7) 400 (3.7) 885 (2.1) 416 (3.9) 332 (4.2) 323 (2.9) 356 (4.5)
Obesity 9142 (13.2) 3344 (9.7) 9097 (13.2) 2900 (27.0) 4119 (9.9) 2860 (26.8) 1916 (24.4) 1599 (14.6) 1965 (24.6)
Peptic ulcer disease 1358 (2.0) 639 (1.9) 1368 (2.0) 136 (1.3) 799 (1.9) 135 (1.3) 91 (1.2) 176 (1.6) 85 (1.1)
Renal disease 13,316 (19.3) 5325 (15.5) 13,311 (19.3) 2099 (19.6) 6917 (16.6) 2104 (19.7) 1068 (13.6) 2383 (21.7) 1098 (13.7)
Smoking 6542 (9.5) 2410 (7.0) 6534 (9.5) 1085 (10.1) 2979 (7.1) 1074 (10.0) 887 (11.3) 1181 (10.8) 952 (11.9)
Viral hepatitis 504 (0.7) 218 (0.6) 528 (0.8) 52 (0.5) 281 (0.7) 47 (0.4) 36 (0.5) 58 (0.5) 34 (0.4)
History of cancer 11,034 (16.0) 4599 (13.3) 11,068 (16.0) 1564 (14.6) 5699 (13.7) 1559 (14.6) 1240 (15.8) 1576 (14.4) 1279 (16.0)
Peritoneal dialysis 33 (0.0) 27 (0.1) 36 (0.1) NTSR 32 (0.1) NTSR NTSR NTSR NTSR
Prior medication useb
ACEI 32,481 (47.1) 17,161 (49.8) 32,399 (47.0) 4995 (46.6) 20,722 (49.6) 5004 (46.8) 3534 (45.0) 5175 (47.1) 3657 (45.8)
ARB 21,700 (31.4) 8771 (25.4) 21,739 (31.5) 3637 (33.9) 11,293 (27.1) 3587 (33.6) 2962 (37.7) 3267 (29.8) 3021 (37.8)
Aspirin 2570 (3.7) 1236 (3.6) 2570 (3.7) 568 (5.3) 1485 (3.6) 559 (5.2) 378 (4.8) 361 (3.3) 391 (4.9)
Beta blockers 34,125 (49.4) 14,687 (42.6) 34,161 (49.5) 5116 (47.7) 18,203 (43.6) 5086 (47.6) 3817 (48.6) 5020 (45.7) 3920 (49.1)
Calcium channel blockers 25,268 (36.6) 11,387 (33.0) 25,178 (36.5) 3587 (33.4) 14,127 (33.8) 3535 (33.1) 2629 (33.5) 3834 (34.9) 2713 (34.0)
Lactulose 896 (1.3) 376 (1.1) 882 (1.3) 90 (0.8) 477 (1.1) 89 (0.8) 50 (0.6) 102 (0.9) 62 (0.8)
Omega-3 2068 (3.0) 712 (2.1) 2135 (3.1) 389 (3.6) 1038 (2.5) 389 (3.6) 341 (4.3) 318 (2.9) 358 (4.5)
Rifaximin 58 (0.1) 19 (0.1) 60 (0.1) 11 (0.1) 25 (0.1) NTSR NTSR NTSR NTSR
Statins 49,068 (71.1) 22,641 (65.7) 48,928 (70.9) 7841 (73.1) 28,040 (67.2) 7720 (72.2) 5980 (76.2) 8011 (73.0) 6061 (75.9)
Loop diuretics 11,631 (16.8) 4933 (14.3) 11,642 (16.9) 2196 (20.5) 5926 (14.2) 2172 (20.3) 1095 (14.0) 1403 (12.8) 1069 (13.4)
Other diuretics 16,826 (24.4) 8056 (23.4) 16,910 (24.5) 2766 (25.8) 9954 (23.8) 2808 (26.3) 1944 (24.8) 2544 (23.2) 2031 (25.4)
Thiazide diuretics 10,457 (15.1) 5183 (15.0) 10,334 (15.0) 1671 (15.6) 6157 (14.7) 1634 (15.3) 1116 (14.2) 1562 (14.2) 1140 (14.3)
Aldosterone antagonists 1529 (2.2) 593 (1.7) 1491 (2.2) 349 (3.3) 712 (1.7) 332 (3.1) 197 (2.5) 235 (2.1) 225 (2.8)
Metformin 49,045 (71.1) 22,373 (64.9) 49,086 (71.2) 7144 (66.6) 27,765 (66.5) 7127 (66.7) 6051 (77.1) 7409 (67.5) 6182 (77.4)
Sulfonylureas 35,193 (51.0) 18,047 (52.4) 35,504 (51.5) 5094 (47.5) 22,742 (54.5) 5128 (48.0) 4008 (51.1) 5910 (53.8) 4102 (51.4)
Thiazolidinediones – – – – – – – – –
DPP4i – – – 3254 (30.3) 7456 (17.9) 3430 (32.1) 3369 (42.9) 3331 (30.3) 3592 (45.0)
GLP1RA 1469 (2.1) 815 (2.4) 1596 (2.3) – – – 1198 (15.3) 501 (4.6) 1317 (16.5)
SGLT2i 331 (0.5) 100 (0.3) 351 (0.5) 247 (2.3) 174 (0.4) 239 (2.2) – – –
Long-acting insulin 10,803 (15.7) 5058 (14.7) 10,852 (15.7) 3919 (36.5) 5896 (14.1) 3902 (36.5) 2458 (31.3) 1754 (16.0) 2629 (32.9)
Measures of healthcare utilization in year prior to index dateb
Low-income subsidy (LIS) status
0 – no subsidy 38,026 (55.1) 17,261 (50.1) 38,242 (55.4) 7000 (65.2) 20,815 (49.9) 6735 (63.0) 5656 (72.1) 6889 (62.7) 5719 (71.6)
1–100 premium subsidy 27,451 (39.8) 15,013 (43.6) 27,120 (39.3) 3172 (29.6) 18,398 (44.1) 3575 (33.4) 1914 (24.4) 3626 (33.0) 2034 (25.5)
2 – partial (25–75)
premium subsidy
3550 (5.1) 2190 (6.4) 3617 (5.2) 556 (5.2) 2532 (6.1) 380 (3.6) 279 (3.6) 465 (4.2) 232 (2.9)
Number of HbA1c tests in the past year
0 7352 (10.7) 6513 (18.9) 7658 (11.1) 1102 (10.3) 7250 (17.4) 1153 (10.8) 353 (4.5) 1507 (13.7) 410 (5.1)
1 11,907 (17.2) 6649 (19.3) 11,533 (16.7) 1474 (13.7) 7574 (18.1) 1426 (13.3) 900 (11.5) 1684 (15.3) 826 (10.3)
2 16,796 (24.3) 7635 (22.2) 16,000 (23.2) 2282 (21.3) 9236 (22.1) 2236 (20.9) 1825 (23.3) 2442 (22.2) 1700 (21.3)
≥3 32,972 (47.8) 13,667 (39.7) 33,788 (49.0) 5870 (54.7) 17,685 (42.4) 5874 (55.0) 4771 (60.8) 5347 (48.7) 5048 (63.2)
Number of LDL tests in the past year
0 11,682 (16.9) 8413 (24.4) 12,065 (17.5) 1758 (16.4) 9506 (22.8) 1798 (16.8) 801 (10.2) 2119 (19.3) 849 (10.6)
1 19,513 (28.3) 9703 (28.2) 19,084 (27.7) 2901 (27.0) 11,506 (27.6) 2802 (26.2) 2114 (26.9) 3124 (28.5) 2086 (26.1)
Table 1 (continued)


























2 18,132 (26.3) 7979 (23.2) 17,383 (25.2) 2715 (25.3) 9937 (23.8) 2699 (25.3) 2173 (27.7) 2745 (25.0) 2110 (26.4)
≥3 19,700 (28.5) 8369 (24.3) 20,447 (29.6) 3354 (31.3) 10,796 (25.9) 3391 (31.7) 2761 (35.2) 2992 (27.2) 2938 (36.8)
Flu shot received in
past year
37,731 (54.7) 16,254 (47.2) 37,780 (54.8) 6089 (56.8) 20,200 (48.4) 6013 (56.3) 4883 (62.2) 5907 (53.8) 4968 (62.2)
Number of hospitalizations in the past year
0 56,180 (81.4) 28,873 (83.8) 56,191 (81.5) 9311 (86.8) 34,944 (83.7) 9228 (86.3) 7073 (90.1) 9536 (86.8) 7161 (89.7)
1 7204 (10.4) 3313 (9.6) 7266 (10.5) 939 (8.8) 4009 (9.6) 970 (9.1) 553 (7.0) 904 (8.2) 598 (7.5)
2 3321 (4.8) 1333 (3.9) 3184 (4.6) 319 (3.0) 1627 (3.9) 303 (2.8) 168 (2.1) 341 (3.1) 141 (1.8)
≥3 2322 (3.4) 945 (2.7) 2337 (3.4) 159 (1.5) 1165 (2.8) 188 (1.8) 55 (0.7) 199 (1.8) 84 (1.0)
Number of days spent in the hospital in the past year
0 56,180 (81.4) 28,873 (83.8) 56,191 (81.5) 9311 (86.8) 34,944 (83.7) 9228 (86.3) 7073 (90.1) 9536 (86.8) 7161 (89.7)
1–2 3133 (4.5) 1490 (4.3) 3145 (4.6) 452 (4.2) 1825 (4.4) 473 (4.4) 275 (3.5) 414 (3.8) 302 (3.8)
3–5 3289 (4.8) 1435 (4.2) 3305 (4.8) 433 (4.0) 1739 (4.2) 430 (4.0) 244 (3.1) 429 (3.9) 244 (3.1)
5–10 1732 (2.5) 780 (2.3) 1705 (2.5) 168 (1.6) 916 (2.2) 173 (1.6) 101 (1.3) 156 (1.4) 105 (1.3)
>10 4693 (6.8) 1886 (5.5) 4632 (6.7) 364 (3.4) 2321 (5.6) 385 (3.6) 156 (2.0) 445 (4.1) 172 (2.2)
Number of emergency department visits in the past year
0 48,019 (69.6) 25,361 (73.6) 47,994 (69.6) 8080 (75.3) 30,621 (73.4) 8013 (75.0) 6028 (76.8) 8211 (74.8) 6099 (76.4)
1 13,052 (18.9) 5816 (16.9) 13,114 (19.0) 1769 (16.5) 7090 (17.0) 1807 (16.9) 1247 (15.9) 1833 (16.7) 1255 (15.7)
≥2 7956 (11.5) 3287 (9.5) 7871 (11.4) 879 (8.2) 4034 (9.7) 870 (8.1) 574 (7.3) 936 (8.5) 630 (7.9)
Number of physician encounters in the past year
0 2055 (3.0) 2317 (6.7) 2054 (3.0) 391 (3.6) 2547 (6.1) 406 (3.8) 76 (1.0) 580 (5.3) 76 (1.0)
1–3 4183 (6.1) 3641 (10.6) 4177 (6.1) 689 (6.4) 4030 (9.7) 704 (6.6) 298 (3.8) 994 (9.1) 293 (3.7)
4–6 5713 (8.3) 3454 (10.0) 5728 (8.3) 757 (7.1) 4030 (9.7) 755 (7.1) 592 (7.5) 1045 (9.5) 575 (7.2)
≥7 57,076 (82.7) 25,052 (72.7) 57,021 (82.7) 8891 (82.9) 31,138 (74.6) 8824 (82.6) 6883 (87.7) 8361 (76.1) 7040 (88.2)
Number of gastroenterologist visits in the past year
0 59,121 (85.6) 30,507 (88.5) 59,234 (85.9) 9140 (85.2) 36,733 (88.0) 9166 (85.7) 6673 (85.0) 9679 (88.2) 6763 (84.7)
1 4077 (5.9) 1653 (4.8) 3862 (5.6) 689 (6.4) 2074 (5.0) 653 (6.1) 528 (6.7) 588 (5.4) 549 (6.9)
2 2813 (4.1) 1094 (3.2) 2686 (3.9) 491 (4.6) 1393 (3.3) 416 (3.9) 336 (4.3) 359 (3.3) 351 (4.4)
≥3 3016 (4.4) 1210 (3.5) 3197 (4.6) 408 (3.8) 1545 (3.7) 455 (4.3) 312 (4.0) 354 (3.2) 322 (4.0)
Number of endocrinologist visits in the past year
0 60,351 (87.4) 32,025 (92.9) 60,986 (88.4) 8029 (74.8) 38,296 (91.7) 8233 (77.0) 6078 (77.4) 9750 (88.8) 6145 (77.0)
1 2947 (4.3) 818 (2.4) 2080 (3.0) 819 (7.6) 1114 (2.7) 502 (4.7) 372 (4.7) 357 (3.3) 382 (4.8)
2 1944 (2.8) 504 (1.5) 1619 (2.3) 504 (4.7) 706 (1.7) 455 (4.3) 323 (4.1) 242 (2.2) 301 (3.8)
≥3 3785 (5.5) 1117 (3.2) 4293 (6.2) 1376 (12.8) 1629 (3.9) 1499 (14.0) 1076 (13.7) 631 (5.7) 1156 (14.5)
Year of initiation
2008 4123 (6.0) 7099 (20.6) 14,059 (20.4) 427 (4.0) 7696 (18.4) 1594 (14.9) – – –
2009 5085 (7.4) 7892 (22.9) 15,362 (22.3) 466 (4.3) 8874 (21.3) 1852 (17.3) – – –
2010 6187 (9.0) 6298 (18.3) 12,420 (18.0) 578 (5.4) 7373 (17.7) 1715 (16.0) – – –
2011 9232 (13.4) 3829 (11.1) 7319 (10.6) 934 (8.7) 4765 (11.4) 1129 (10.6) – – –
2012 10,825 (15.7) 2101 (6.1) 4025 (5.8) 1484 (13.8) 2740 (6.6) 721 (6.7) 0 (0) 281 (2.6) 189 (2.4)
2013 11,457 (16.6) 2345 (6.8) 4881 (7.1) 2148 (20.0) 3247 (7.8) 1026 (9.6) 550 (7.0) 3408 (31.0) 2359 (29.5)
2014 12,749 (18.5) 2794 (8.1) 6202 (9.0) 2473 (23.1) 4085 (9.8) 1467 (13.7) 3279 (41.8) 4257 (38.8) 3193 (40.0)
2015 9369 (13.6) 2106 (6.1) 4711 (6.8) 2218 (20.7) 2965 (7.1) 1185 (11.1) 4020 (51.2) 3034 (27.6) 2242 (28.1)
Abbreviations: SGLT2i, sodium-glucose cotransporter-2 inhibitors; DPP4i, dipeptidyl peptidase-4 inhibitors; GLP1RA, glucagon-like peptide-1 receptor agonist; TZD, thiazolidinediones;
AMI, acute myocardial infarction; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting-enzyme inhib-
itor; ARB, angiotensin receptor blockers; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; NTSR, number too small to reportc.
a Weighted by standardizing the comparator drug initiators to the population of index treatment initiators, using the propensity score odds (PS/(1-PS)), to estimate the treatment effect
in the treated (ATT).
b All baseline characteristics measured in the one year (365 days) prior to date of cohort drug initiation.
c Number too small to report (<11), per Medicare Data Use Agreement.randomized study by Yan et al comparing the efficacy of liraglutide,
sitagliptin or insulin glargine (on background metformin) for NAFLD
found that add-on liraglutide and sitagliptin led to comparable reduc-
tions in liver fat, whereas insulin glargine did not.35 However, a dedi-
cated RCT by Cui et al examining the effects of sitagliptin (vs placebo)
on NAFLD in patients with T2D did not demonstrate improvement in
hepatic fat content.14
4.2. Gender and other subgroup differences
In subgroup analyses,we observed higher estimated aHRs for cirrho-
sis amongwomen, in particular for theDPP4i vs. TZD comparison (Fig. 2,
primary definition,women, aHR 1.50 [95%CI 1.04, 2.16];men; 0.86 [95%
CI 0.59–1.25]). We observed similar trends for GLP1RA and SGLT2i, vs.
TZD, though estimates were more imprecise in these comparisons.
The reasons for this gender difference are unclear, although data on
NAFLD suggest an important role of sex hormones, as men are at higherrisk during reproductive years, while women are at higher risk after
menopause.36 It is therefore feasible that the metabolically distinct
livers of men and women interact differently with medications, includ-
ing GLDs. Some studies have reported TZD to be more effective in
women than inmen, though data aremixed.37,38 Evidence does not sug-
gest meaningful differences in efficacy of GLP1RA and SGLT2i by
gender,37–39 though women are more likely to experience side effects
of these medications (e.g., nausea and vomiting associated with
GLP1RA).37,38 It is plausible that more frequent examinations and test-
ing in response to medication-related symptoms could lead to earlier
discovery of cirrhosis (e.g., via abdominal imaging or endoscopy) in
women compared to men. It is notable that sex differences also exist
in other forms of CLD40 – how this is influenced by GLDs is largely un-
known, and an interesting area for future research.
We additionally observed a higher estimated hazard of cirrhosis
among initiators of GLP1RAvs. TZDs (aHR1.82 [95% CI 1.09, 3.06]) in pa-
tients not on baseline insulin, whereas this was not the case for those on
Table 2
Crude and adjusted hazard ratio (HR) estimates for incident liver cirrhosiswith second-line glucose-lowering drug initiation (365-daywashout period, As-treated analysis, 1% asymmetric
propensity score trimming).















AT Analysis DPP4i 69,027 0.66 (0.33–1.51) 78,778 220 2.8 (2.4–3.2) 1.09 (0.86–1.39) 1.15 (0.89–1.50)
TZD 34,464 0.64 (0.33–1.45) 38,393 98 2.6 (2.1–3.1)
IT Analysis DPP4i 69,027 2.08 (0.91–3.00) 131,309 392 3.0 (2.7–3.3) 1.03 (0.88–1.21) 1.06 (0.89–1.26)
TZD 34,464 3.00 (1.52–3.00) 79,036 232 2.9 (2.6–3.3)
GLP1RA vs. TZD
AT Analysis GLP1RA 10,728 0.45 (0.25–0.96) 8264 30 3.6 (2.5–5.2) 1.41 (0.95–2.11) 1.34 (0.82–2.20)
TZD 41,745 0.64 (0.33–1.42) 45,741 121 2.6 (2.2–3.2)
IT Analysis GLP1RA 10,728 1.66 (0.67–3.00) 18,355 57 3.1 (2.4–4.0) 1.06 (0.80–1.41) 0.95 (0.67–1.34)
TZD 41,745 3.00 (1.40–3.00) 93,420 281 3.0 (2.7–3.4)
SGLT2i vs. TZD
AT Analysis SGLT2i 7849 0.40 (0.21–0.70) NTSRb NTSR 1.7 (0.8–3.6) 0.91 (0.38–2.21) 1.16 (0.44–3.08)
TZD 10,980 0.58 (0.30–1.11) 8507 17 2.0 (1.2–3.2)
IT Analysis SGLT2i 7849 0.60 (0.31–1.03) NTSR NTSR 1.6 (0.8–3.1) 0.62 (0.30–1.29) 0.80 (0.38–1.67)
TZD 10,980 1.10 (0.51–1.75) 12,953 35 2.7 (1.9–3.8)
Abbreviations: SGLT2i, sodium-glucose cotransporter-2 inhibitors; DPP4i, dipeptidyl peptidase-4 inhibitors; GLP1RA, glucagon-like peptide-1 receptor agonists; TZD, thiazolidinediones; IQR,
interquartile range; PS, propensity score; AT, as-treated; IT, initial treatment (similar to intention-to-treat approach in randomized controlled trials); NTSR, number too small to reportb.
a Follow-up in IT analyses were capped at 3 years following index date.
b Number too small to report (<11), per Medicare Data Use Agreement.insulin. One potential explanation is that GLP1RA are often initiated in
patients whose glycemic control has worsened such that they necessi-
tate insulin, but who decline or prefer to delay recommended insulin
therapy. Also, patients prescribed GLP1RA in the absence of insulin
may have worse obesity. In both cases, poor metabolic health in this
subgroup may contribute to more rapid progression of liver disease.
Conversely, patientswith baseline insulin use,which is a surrogatemea-
sure of increased diabetes duration or severity, may have experienced
higher baseline cirrhosis risk in both drug groups, whichmay have con-
tributed to the attenuated aHR estimates in that subgroup. We did not
observe these trends in the SGLT2i vs. TZD comparison, although esti-
mates in that analysis were generally difficult to interpret due to low
precision.DPP4i vs. TZD (Cirrhosis Definition 1) GLP1RA vs. TZD (Cir
DPP4i vs. TZD (Cirrhosis Definition 2) GLP1RA vs. TZD (Cir
Fig. 1. SMR-weighteda cumulative incidence (Kaplan-Meier) curves for incident liver cirrhosis fo
analysis, 1% asymmetric propensity score trimming). Abbreviations: SMR, standardizedmortali
inhibitors; GLP1RA, glucagon-like peptide-1 receptor agonists; TZD, thiazolidinediones; HR, ha
index drug initiators, using the propensity score odds (PS/(1-PS)), to estimate the treatment e4.3. Implication of findings
Our findings suggest a possible trend towards greater benefit of TZD
over newer GLDs in terms of cirrhosis risk. Since we included an older
population of patients with T2D, it is likely that NAFLD accounted for a
large proportion of CLD in this study. Thus, while our results reflect
the impact of GLDs on all-cause cirrhosis, this may be largely driven
by known effects in NAFLD, rather than impact on other forms of CLD
(i.e. viral, alcoholic). One small study examining hepatic steatosis by
magnetic resonance spectroscopy found that pioglitazone was able to
reduce hepatic steatosis in individuals with human immunodeficiency
virus and hepatitis C coinfection.10 However, data examining use of pi-
oglitazone and other GLDs in non-NAFLD CLD are limited, and furtherrhosis Definition 1) SGLT2i vs. TZD (Cirrhosis Definition 1)
rhosis Definition 2) SGLT2i vs. TZD (Cirrhosis Definition 2)
llowing second-line glucose-lowering drug initiation (365-daywashout period, as-treated
ty ratio; SGLT2i, sodium-glucose cotransporter-2 inhibitors; DPP4i, dipeptidyl peptidase-4
zard ratio. aWeighted by standardizing the comparator drug initiators to the population of
ffect in the treated (ATT).
Table 3
Crude and adjusted hazard ratio (HR) estimates for incident liver cirrhosis under Alternative OutcomeDefinitions (365-daywashout period, as-treated analysis, 1% asymmetric propensity
score trimming).
High specificity definitionsa High sensitivity definitionsa
Comparison Cohort Number of
patients













Lapointe et al., 2018
(Definitions 1 & 2)








TZD 34,464 2.6 (2.1–3.1) 4.6 (4.0–5.4)
Nehra et al, 2013
(Definitions 3 & 4)








TZD 34,464 1.0 (0.7–1.3) 5.8 (5.1–6.6)
GLP1RA vs. TZD
Lapointe et al, 2018
(Definitions 1 & 2)








TZD 41,745 2.6 (2.2–3.2) 4.9 (4.3–5.6)
Nehra et al, 2013
(Definitions 3 & 4)








TZD 41,745 1.0 (0.7–1.3) 5.9 (5.3–6.7)
SGLT2i vs. TZD
Lapointe et al, 2018
(Definitions 1 & 2)








TZD 10,980 2.0 (1.2–3.2) 4.8 (3.6–6.6)
Nehra et al, 2013
(Definitions 3 & 4)








TZD 10,980 0.8 (0.4–1.7) 5.5 (4.2–7.4)
Abbreviations: SGLT2i, sodium-glucose cotransporter-2 inhibitors; DPP4i, dipeptidyl peptidase-4 inhibitors; GLP1RA, glucagon-like peptide-1 receptor agonists; TZD, thiazolidinediones;
IQR, interquartile range; PS, propensity score; AT, as-treated; IT, initial treatment (similar to intention-to-treat approach in randomized controlled trials). aDefinition 1: 456.1; 571.2;
571.5; INPATIENT ONLY (specificity 91–96%; sensitivity 57–77%); Definition 2: 456.1; 571.2; 571.5; INPATIENT (INPT) & OUTPATIENT (OUTPT) (specificity 61–77%; sensitivity 98–
99%); Definition 3: 456.0; 456.2; 456.21; 572.4; INPT/OUTPT (specificity 98.3%; sensitivity 11.3%); Definition 4: 456.0; 456.1; 456.2; 456.21; 571.2; 571.5; 572.2; 572.3; 572.4; 567.23;
INPT/OUTPT (specificity 43%; sensitivity 97.7%).studies would be needed before TZD could be recommended above
other GLDs for the purpose of reducing risk of progression to cirrhosis.4.4. Strengths and limitations
Ours is the first study to examine the impact of second-line GLDs on
risk of incident cirrhosis in a large, nationally-representative population
of older adult patients. The active comparator, new user design provides
implicit control for confounding by indication among patients receiving
similar-lineGLDs, and the restriction to patientswith ≥2 prescriptions of
a study drug increases confidence that patients are continuously taking
those drugs. Finally, as shown in standardized difference plots, propen-
sity score weighting methods were successful in controlling for mea-
sured confounders.
There were important limitations to this study. First, longer drug ex-
posure timesmay benecessary to detect significant differences between
GLDs, since it can take many years to develop and diagnose cirrhosis. In
our study, the relatively short (0.40–0.66 years) on-treatment times ob-
served in theMedicare FFS population precluded our ability to establish
a robust causal relationship between second-lineGLDuse and incidence
of cirrhosis. Second, our studywas not linked to the electronic health re-
cord, so we were unable to adjust for several relevant confounding fac-
tors, such as blood pressure, HbA1c, lipids, and importantly, body mass
index. Notably, obesity is known to be sub-optimally captured in ad-
ministrative claims data, with high specificity but poor sensitivity. We
observed higher prevalence of obesity codes among new users of
GLP1RA and SGLT2i than in TZD users; while reasonable covariate bal-
ance was achieved after propensity score weighting, we acknowledge
the possibility for residual confounding. We conducted a sensitivity
analysis to examine the impact of baseline obesity and found nomean-
ingful difference in results, though this should be interpreted with cau-
tion since coding for obesity may be incomplete in clinical practice.
Future head-to-head pragmatic randomized trials comparing liver ef-
fects of TZDs to other second-line GLDs may help to address issues of
baseline unmeasured confounding.Finally, when interpreting results of our study, it is important to con-
sider the natural history of cirrhosis and outcome definitions used. Cir-
rhosis can take years to develop, and diagnoses often occur when
patients transition from compensated to decompensated disease; the
latter of which may necessitate hospitalization.41 Since we anticipated
low counts for cirrhosis over our 8-year study period, we examined
multiple validated coding definitions (Appendix Table 3). Our primary
coding definition required ICD-9 codes to be placed in the hospital set-
ting only, while our secondary definition included the same codes but
allowed them to be placed in either inpatient or outpatient settings.
Since most cases of compensated cirrhosis receive care in the primary
care setting,42 our secondary definition had greater sensitivity for de-
tecting cirrhosis and likely captured more individuals with both stable
and decompensated disease, vs. only hospitalized patients with more
severe disease or clinical decompensation (i.e., primary definition).
Event rates for cirrhosiswere expectedly higherwith our secondary def-
inition, and comparisons were better powered. Larger studies with
higher event rates would be needed to provide additional insight into
the impact of GLDs on cirrhosis risk when very specific (yet less sensi-
tive) outcomes definitions are used.
5. Conclusion
In conclusion,we observed a possible trend towards lower risk of in-
cident cirrhosis with TZD use vs. newer second-line GLDs, although
some uncertainty remains due to imprecise estimates resulting from
short durations of on-treatment follow-up in this population. Our re-
sults mirror preliminary data on the impact of GLDs on NAFLD, and
these findings merit further study to better understand which GLDs
should be prioritized for reducing cirrhosis risk among patients with
type 2 diabetes.
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